MRD (Minimal Residual Disease) Testing Market Landscape: Key Insights and Growth Predictions (2025-2032)
The market, valued in 2023, is expected to experience significant growth by 2032, driven by a strong compound annual growth rate (CAGR) from 2025 to 2032.
Analysis of the Market | Research Report [2025-2032] - https://www.globalmarketstatis....tics.com/market-repo
The "MRD (Minimal Residual Disease) Testing Market" Research Report provides a comprehensive analysis of industry trends, growth, and opportunities, categorized by types (Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)) and regional outlook. It includes forecasts spanning from 2025 to 2032.
Browse the detailed TOC of the MRD (Minimal Residual Disease) Testing Market report, featuring comprehensive tables, figures, and charts that offer exclusive data, vital statistics, key trends, and insights into the competitive landscape of this niche sector.
Who is the largest manufacturers of MRD (Minimal Residual Disease) Testing Market worldwide?
Cergentis B.V. (Netherlands)
Natera (United States)
NeoGenomics Laboratories (United States)
ICON plc (Ireland)
Asuragen (United States)
Invivoscribe (United States)
Bio-Rad Laboratories (United States)
ARUP Laboratories (United States)
Inivata (United Kingdom)
Sysmex Corporation (Japan)
Guardant Health (United States)
Adaptive Biotechnologie (United States)
Mission Bio (United States)
LabCorp (United States)
Quest Diagnostics (United States)
Opko Health (United States)
ArcherDX (Invitae) (United States)
Market Analysis | Report [2025-2032] @ - https://www.globalmarketstatis....tics.com/market-repo
